Tous Actualités
Suivre
Abonner Astellas Pharma Europe Limited

Astellas Pharma Europe Limited

Astellas Enters Into License Agreement With TOLMAR

Tokyo (ots/PRNewswire)

Astellas Pharma Inc.
announced today that its European subsidiary Astellas Pharma Europe
Ltd.("Astellas Pharma Europe", headquarters: Stains, U.K.)" acquired
the license for commercialization of  the treatment for advanced
prostate cancer Eligard(R) from TOLMAR Inc.  ("TOLMAR", headquarters:
Colorado, U.S.A.) on December 22, 2010 in a  selection of Asian,
Middle Eastern, North African and Commonwealth of  Independent States
(CIS) countries.
Eligard is a luteinizing hormone-releasing hormone (LHRH) agonist
which Astellas Pharma Europe in-licensed from TOLMAR and Astellas
Pharma Europe registered and launched Eligard successfully in the
vast majority of European countries. Under the terms of the new
agreement, the commercialization of Eligard will be expanded to the
Middle East, North Africa, CIS, Central Asia and Asian markets such
as China, Taiwan, Thailand, Hong Kong, the Philippines and Indonesia.
Astellas puts a high strategic focus on the therapeutic area of
urology, by commercializing a treatment for overactive bladder,
Vesicare(R), and a treatment for functional symptoms of benign
prostatic hyperplasia, Omnic(R), Omnic Ocas(R) (sold under the names
Harnal(R) in Japan) This new agreement could reinforce the presence
of the therapeutic area, as well as a bridgehead for the entry into
the therapeutic area of oncology, Astellas' third prioritized area
alongside urology and transplant in emerging markets including Asia.
About Astellas
Astellas Pharma Inc., located in Tokyo, Japan, is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative and reliable
pharmaceutical products. Astellas has approximately 16,000 employees
worldwide. The organization is committed to becoming a global
category leader in urology, immunology & infectious diseases,
neuroscience, DM complications & metabolic diseases and oncology. For
more information on Astellas Pharma Inc., please visit our website at
http://www.astellas.com/en.

Contact:

CONTACT: Contacts for inquiries or additional information: Astellas
PharmaInc., Corporate Communications, Tel: +81-3-3244-3201 Fax:
+81-3-5201-7473

Plus de actualités: Astellas Pharma Europe Limited
Plus de actualités: Astellas Pharma Europe Limited
  • 20.04.2010 – 07:03

    Urology and Transplantation Will Drive Future Growth as Astellas Begins Move into Oncology

    London, April 20, 2010 (ots/PRNewswire) - Today, on the fifth anniversary since its formation, Astellas Pharma Europe has confirmed that it will continue its emphasis on transplantation and urology while moving towards a new vision to build a strong presence in oncology. Astellas has shown robust growth since its creation, expanding its reach into new therapeutic ...

  • 01.12.2009 – 08:07

    Men, Partners and Patients in Europe United Against Prostate Cancer

    Barcelona, Spain (ots/PRNewswire) - - New Survey Highlights Need for Education Resources, Critical Role of Physician in Patient Communication and Importance of Maintaining Normal Lifestyle During Treatment Findings from a survey of European prostate cancer patients, presented at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC) in ...

  • 22.06.2009 – 13:08

    NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)

    San Mateo, California and Staines, England (ots/PRNewswire) - - Conference Call Today at 9:00am ET - Covers Europe, Middle East and Africa - Includes Licensing Option and Development Funding for NGX-1998 NeurogesX, Inc. (NASDAQ: NGSX) and Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo based Astellas Pharma Inc. announced ...